pipeline-prospector-insert-v1
X

Find Gastroenterology Clinical Drug Pipeline Developments & Deals

A collaboration with SCORR Marketing

Loading...

All Data

Filters Filter refresh
×
FILTER DATA :
Study Phase filter
    Country filter
      News Type filter
        Company filter
          Product Type filter
            refresh

            Product Type

            Development Status

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Glutamine

            Therapeutic Area: Gastroenterology

            Highest Development Status: Phase I Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable January 29, 2020

            Details:

            A marginal but decreased size in some of the diverticula compared to the baseline. Indications of Healing and Normalization of Bowel Movements Observed in the Initial Patient.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Brazikumab

            Therapeutic Area: Gastroenterology

            Highest Development Status: Phase II/ Phase III Product Type: Large molecule

            Partner/Sponsor/Collaborator: AstraZeneca

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Divestment January 27, 2020

            Details:

            AstraZeneca will acquire brazikumab, in Phase 2b/3 development for Crohn's Disease and in Phase 2 development for ulcerative colitis, including global development and commercial rights.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Fosnetupitant Chloride,Palonosetron

            Therapeutic Area: Gastroenterology

            Highest Development Status: Approved Product Type: Small molecule

            Partner/Sponsor/Collaborator: Helsinn Group

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Licensing Agreement January 27, 2020

            Details:

            Berlin-Chemie AG has been granted exclusive rights to import, distribute, promote, market and sell AKYNZEO® and ONICIT® in Russia and CIS region to manage chemotherapy-induced nausea and vomiting.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Brilacidin

            Therapeutic Area: Gastroenterology

            Highest Development Status: Phase I Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable January 24, 2020

            Details:

            Brilacidin utilizing new delayed release technology for targeted delivery directly to colon.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): ALPN-101

            Therapeutic Area: Gastroenterology

            Highest Development Status: Preclinical Product Type: Large molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable January 24, 2020

            Details:

            The new data demonstrate the unique potency of ALPN-101 as measured by in vitro assays involving PBMC’s from patients with Crohn’s Disease or Ulcerative colitis and in vivo mouse models of colitis.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Metoclopramide

            Therapeutic Area: Gastroenterology

            Highest Development Status: Phase III Product Type: Small molecule

            Partner/Sponsor/Collaborator: Eversana

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Agreement January 23, 2020

            Details:

            Under the terms of the agreement, Evoke retains Gimoti NDA rights as well as all legal, regulatory and production obligations, while EVERSANA will sell and supply Gimoti in the United States.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Linaclotide

            Therapeutic Area: Gastroenterology

            Highest Development Status: Approved Product Type: Small molecule

            Partner/Sponsor/Collaborator: Teva Pharmaceuticals

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Agreement January 23, 2020

            Details:

            Pursuant to the terms of the settlement, Ironwood and Allergan will grant Teva a license to market its 145 mcg and 290 mcg generic version of LINZESS in U.S.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): GB004

            Therapeutic Area: Gastroenterology

            Highest Development Status: Phase I Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable January 23, 2020

            Details:

            Gossamer bio is conducting a Phase 1 multiple ascending dose study of GB004 in healthy volunteers with Gut Biopsies.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Galacto-oligosaccharide

            Therapeutic Area: Gastroenterology

            Highest Development Status: Phase II/ Phase III Product Type: Large molecule

            Partner/Sponsor/Collaborator: Qualigen

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Merger January 21, 2020

            Details:

            The merged company will focus on the development of Qualigen’s nanotechnology therapies for the treatment of cancer and infectious diseases, while also continuing to operate its profitable diagnostic business.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): KAN-101

            Therapeutic Area: Gastroenterology

            Highest Development Status: IND Enabling Product Type: Undisclosed

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable January 21, 2020

            Details:

            Anokion plans to initiate its multi-center Phase 1 study for KAN-101 in people with celiac disease in the first quarter of 2020.

            PharmaCompass